Dihydroxyaluminum Sodium Carbonate

57 interactions
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Cabotegravir Cefuroxime Deferasirox Octreotide Injection Erdafitinib
15 Major 34 Moderate 8 Minor
All (57) Major (15) Moderate (34) Minor (8)

Major

Dihydroxyaluminum Sodium Carbonate Acalabrutinib Calquence Reduced acalabrutinib exposure Details Dihydroxyaluminum Sodium Carbonate Cabotegravir Apretude Reduced cabotegravir plasma concentrations Details Dihydroxyaluminum Sodium Carbonate Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Dihydroxyaluminum Sodium Carbonate Deferasirox Exjade Decreased deferasirox effectiveness Details Dihydroxyaluminum Sodium Carbonate Digoxin Cardoxin® Reduced digoxin exposure Details Dihydroxyaluminum Sodium Carbonate Erdafitinib Balversa Altered serum phosphate levels Details Dihydroxyaluminum Sodium Carbonate Ezetimibe Zetia Reduced ezetimibe exposure Details Dihydroxyaluminum Sodium Carbonate Gefitinib Iressa Decreased exposure of gefitinib Details Dihydroxyaluminum Sodium Carbonate Hydroxychloroquine Plaquenil Reduced hydroxychloroquine exposure Details Dihydroxyaluminum Sodium Carbonate Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Dihydroxyaluminum Sodium Carbonate Ketoconazole Topical Extina® Foam Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Dihydroxyaluminum Sodium Carbonate Mefenamic Acid Ponstel® Increased exposure to mefenamic acid Details Dihydroxyaluminum Sodium Carbonate Neratinib Nerlynx Decreased neratinib exposure Details Dihydroxyaluminum Sodium Carbonate Octreotide Bynfezia Decreased octreotide bioavailability Details Dihydroxyaluminum Sodium Carbonate Octreotide Injection Bynfezia Decreased octreotide bioavailability Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.